Objectives: This study aimed to compare a modified Magee equation with Oncotype DX (Genomic Health, Redwood City, CA) recurrence score (RS) and identify patients who are unlikely to benefit from Oncotype DX.
Results:
The Pearson correlation coefficient (r) for the Magee equation and Oncotype DX RS was 0.6645 (P < .00001), and the overall agreement was 66.4%. All cases (11.6%) with a Magee equation RS greater than 30 or 11 or less had been correctly predicted to have either high Oncotype DX RS or low Oncotype DX RS, respectively.
Conclusions:
The modified Magee equation is able to identify up to 12% patients who are unlikely to benefit from Oncotype DX testing. Using the modified Magee equation RS on these patients would be an alternative to Oncotype DX, leading to cost savings.
Breast cancer is the most frequent cancer in women and the second most frequent cause of cancer death among women within the United States. 1 More than half of breast cancer cases are estrogen receptor (ER) positive. 2 The combined antiestrogen therapy and chemotherapy have significantly reduced recurrence frequency and improved survival rate in certain populations of patients with ER-positive breast cancer. 3 However, these therapies, especially chemotherapy, have toxic side effects; therefore, identifying patients who are more likely to benefit from chemotherapy is important. Clinicopathologic factors, including tumor size, histologic grade, lymph node status, and breast cancer biomarkers (ER, progesterone receptor [PR] , and human epidermal growth factor receptor 2 [HER2]), have been used to determine if the patient needs systemic therapy and which therapies will be used. [4] [5] [6] [7] [8] [9] [10] Recently, molecular tests have been clinically used to evaluate the patient's recurrence risk and predict prognosis by assessing the genomic profile of the tumor. 11, 12 Oncotype DX (Genomic Health, Redwood City, CA) is one such molecular test that has been widely accepted for clinical use within the United States and Canada. Oncotype DX, a reverse transcription-polymerase chain reaction assay of 21 genes, generates a recurrence score (RS) to predict the prognosis and chemotherapy benefits for ER-positive, HER2-negative patients with invasive breast cancer. 13, 14 Oncotype DX quantifies the expression of 16 cancer-related genes after normalization using the remaining five genes to calculate the RS, which is reported as a number that is divided into low (<18), intermediate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , or high (>30) recurrence risk categories.
Many studies have demonstrated that routine histopathologic and immunohistochemical variables can provide similar prognostic information to that of the Oncotype DX RS. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] This is not surprising because four of the 16 genes (ER, PR, HER2, and Ki-67) measured in Oncotype DX are assessed in the routine pathologic evaluation at the protein level by immunohistochemistry (IHC). 28 Tumor proliferation is also assessed in routine pathologic evaluation by counting mitosis as this is a component of tumor grade. Magee equations are derived by linear regression analysis using several pathologic variables and semiquantitative immunohistochemical results of ER, PR, HER2, and Ki-67 to calculate an RS that highly correlates with the Oncotype DX RS and provides similar information to that from Oncotype DX. 15, 16 Our goal was to independently examine the correlation between a modified Magee equation RS and Oncotype DX RS and investigate whether the modified Magee equation could categorize patients with ER-positive, HER2-negative breast cancer into the same low-risk or high-risk category as Oncotype DX. consisting of a chromosome 17 centromeric probe and a separate HER2 probe) was performed on most cases with in-house core needle biopsy, and the FISH results were interpreted by fellowship-trained molecular pathologists. The Nottingham grade (NG) was calculated using the Nottingham modification of the Bloom-Richardson system.
Materials and Methods

Patients and Data Retrieval
Study Design
Three Magee equations (1, 2, and 3) using different combinations of standard histopathologic variables (Nottingham Score [NS], ER, PR, HER2, Ki-67, and tumor size) have been previously reported to predict the Oncotype DX RS, available at the website of the pathology department at Magee-Womens Hospital of the University Pittsburgh Medical Center (http:// path.upmc.edu/onlineTools/mageeequations.html). Since many cases in our study cohort did not have Ki-67 results, Magee equation 2 was used, which does not require a Ki-67 value to calculate the Magee RS. The H-score for ER or PR used in the original Magee equation 2 is calculated by adding the total of the stained percentage multiplied by intensity for all three different intensity grades (0-3) to obtain a value from 0 to 300. The H-score for ER and PR in our series was estimated to obtain a value from 0 to 300 by multiplying the predominant intensity (0-3) by the total stained percentage of cells (0-100). This modification of the Magee equation had been described previously. 29 
Statistical Analysis
All clinicopathologic data were summarized using percentages and descriptive statistics (mean, range, frequencies (Table 1) .
There were consistently significant differences (P < .05) between the Oncotype DX RS risk stratification categories for the modified Magee equation RS, histologic types (more ductal type in higher RS categories), NG and all three NG components (tubule formation score, nuclear pleomorphism score, and mitosis score), ER/PR values by Oncotype DX, HER2 value by Oncotype DX, and ER/PR scores by IHC but not for age, tumor size, and lymph node status (Table 1 ). There were consistently significant differences (P < .05) for PR-positive rate (both by Oncotype DX and by IHC) among the three categories but not for HER2-positive rate and ER-positive rate (by either Oncotype DX or IHC). However, the high-risk group with an Oncotype DX greater than 30 showed significantly more cases with negative ER by Oncotype DX than the other two groups (Table 1) .
There was an overall 67% (292/438) agreement between the modified Magee equation RS and the Oncotype DX RS Table 2 . Following the criteria set by the Oncotype DX RS for low-, intermediate-, and high-risk categories, there were no two-step discordances (discordance between high and low risk) between any modified Magee equation RS and their paired Oncotype DX RS ( Table 2) 
Discussion
The American Society of Clinical Oncology clinical practice guideline recommends the clinician may use the 21-gene RS (Oncotype DX RS) to guide decisions on adjuvant systemic chemotherapy if a patient has ER-positive, HER2-negative breast cancer, and the Oncotype DX assay has been widely accepted in clinical practice across the United State and Canada. Since four of the 16 genes (ER, PR, HER2, and Ki-67) measured as part of the Oncotype DX panel are assessed at the protein level by IHC in the routine diagnostic evaluation of breast cancer, studies have suggested that standard histopathologic variables (including tumor grade and mitotic activity), together with biomarkers evaluated by IHC, can provide information similar to that provided by the Oncotype DX RS. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The Magee equation
is one of such approaches to predict Oncotype DX RS by using different combinations of NG, Ki-67, or tumor size, in addition to semiquantitative ER, PR, and HER2. 15, 16 There were consistently significant differences for tumor grade, mitotic activity, ER, and PR between the Oncotype DX RS risk stratification categories (low, intermediate, and high) but not for tumor size, HER2 status (negative or equivocal), or lymph node status. The tumor grade and PR value consistently showed greater difference between risk stratification categories than ER values, suggesting ER is less important in risk stratification than PR or tumor grade, consistent with the findings in previous studies. [22] [23] [24] [25] [26] [27] The modified Magee equation, which uses standard histopathologic and immunohistochemical variables, could identify a portion of patients with ER-positive breast cancer who may not need Oncotype DX for determining an RS. Indeed, our data demonstrated that all cases with a modified Magee equation RS greater than 30 had an Oncotype DX RS of more than 30, and 100% (n ¼ 40) of cases with a modified Magee equation RS of 11 or less had an Oncotype DX RS less than 18. These cases accounted for 11.6% of all cases with the Oncotype DX test and had been correctly predicted by the modified Magee equation to have a corresponding Oncotype DX RS category. Therefore, patients with a modified Magee equation RS less than 11 or more than 30 may not benefit from an Oncotype DX test. The estimated cost saving from these patients would be $221,850, based on the current list price of $4,350 for the Oncotype DX. This is only for a single institution with a moderate volume of breast cancer cases over a 6-year period. Similar cost saving analysis was also calculated in a previous study using a screening algorithm with the combination of modified Magee equations, histologic criteria, and biomarker results to identify potential cases unlikely to benefit from the Oncotype DX. 29 Our data support this idea with a simplified process and still were able to identify up to 12% Although our findings may implicate that performing Oncotype DX RS on these special types of tumors is less likely to be useful to guide clinical management, the number of these special types (tubular and mucinous types) in our study was too low to draw a definitive conclusion, and further studies with large cohorts of these specific types are warranted. Our study cohort was limited by bias toward patients with an indeterminate clinical risk assessment because the selection of cases for Oncotype DX was based on the oncologists' clinical judgment. Therefore, apparent low-risk or high-risk patients are likely to be underrepresented. Another limitation of our study is the lack of recurrence or overall survival data because the study cohort only included relatively recent cases that did not have sufficient time for clinical follow-up. In our study, ER and PR IHCs were evaluated by a semiquantitative manner. Although such a method might be subjective with a variable range, the overall quality and interobserver agreement for interpretation of these results were ensured by a quality assurance program and a mandatory proficiency test implemented in our institution. In addition, low-grade carcinoma cases with weak ER staining/negative PR staining and high-grade cases with positive ER/PR were reviewed in the current study.
In summary, our data provided more evidence to support that the modified Magee equation RS correctly predicts Oncotype DX RS for most cases, and there should be little difference between these two RS risk categories. However, if a major difference occurs, the pathology, biomarkers, and the block sent for Oncotype DX testing should be thoroughly investigated. Furthermore, the modified Magee equation derived from standard histologic variables and breast biomarker results can be used to stratify patients who are eligible for Oncotype DX testing, identifying up to 12% of patients who are unlikely to benefit from this test and saving unnecessary expenses.
